ライフサイエンスコーパス: Sabin

1 Sabin 2 transmission following the mOPV2 clinical trial

2 Sabin strains of poliovirus used in the manufacture of o

3 Sabin strains used in oral poliovirus vaccines (OPV) can

4 Sabin strains used in the manufacture of oral polio vacc

5 Sabin strains were identified up to 5-8 weeks after the

6 Sabin-2 poliovirus reverts rapidly at nucleotide 481, th

7 campaign in all towns; in Aguascalientes, 1 Sabin 3 was isolated 16 weeks after the campaign, follow

8 her titers than attenuated counterparts PV(1)Sabin and PV(2)W-2, respectively, in primary human monoc

9 cell line, PV(1)Mahoney replicated but PV(1)Sabin did not, while both grew well in HeLa cells.

10 ecular recombinants of PV(1)Mahoney and PV(1)Sabin were assessed, a correlation between neurovirulenc

11 oliovirus isolates related to the serotype 2 Sabin vaccine strain were detected in 21 of 52 sequentia

12 ed by dilution analysis of poliovirus type 2 Sabin in cerebrospinal fluid.

13 V(3)Leon grew weakly, while PV(3)Sabin, PV(2)Sabin, and PV(2) P712 did not replicate in these cells,

14 Although the type 3 Sabin strain is an effective vaccine, polioviruses with

15 PV(3)Leon grew weakly, while PV(3)Sabin, PV(2)Sabin, and PV(2) P712 did not replicate in t

16 Virus 31043 had a Sabin-derived type 3-type 2-type 1 recombinant genome wi

17 ral fecal shedding from infants administered Sabin monovalent poliovirus type 2 vaccine (mOPV2) or lo

18 ion), even though all were protected against Sabin-1.

19 sociated with increased seroresponses to all Sabin types, especially to Sabin type 3.

20 nd rotavirus) infections, interference among Sabin vaccine viruses, and preexisting poliovirus antibo

21 nucleotide difference between the MEF-1 and Sabin 2 strains, resulting in 72 amino acid substitution

22 e entire 5' noncoding regions of Sabin 1 and Sabin 2 were replaced exactly with that of one of the ty

23 r enterovirus strains, including sabin-1 and Sabin-3 RNA.

24 similar for Sabin isolate-Sabin isolate and Sabin isolate-non-Sabin enterovirus recombination after

25 each other and from those of WT Mahoney and Sabin type 3 viruses.

26 for attenuated oral polio vaccines (OPV) and Sabin types 1, 2, and 3.

27 eraction of the IRESs of PV type 3 (PV3) and Sabin type 3 (Sabin3) with polypyrimidine tract-binding

28 ence difference between 7 type 1 strains and Sabin type 1 vaccine strain was found.

29 atefully acknowledge support from the Andrew Sabin Family Fellowship, Center for Radiation Oncology R

30 Poliovirus isolates were identified as Sabin-like or wild type through real-time polymerase cha

31 at experimental IPV produced from attenuated Sabin strain (sIPV) of serotype 1 poliovirus induced ser

32 In attenuated Sabin strains, point mutations within stem-loop V of the

33 progressing rapidly, and the live attenuated Sabin strains in the oral poliovirus vaccine (OPV) are b

34 xperimental IPV produced from the attenuated Sabin strain (sIPV) with those of conventional IPV (cIPV

35 d that a 1,000-fold excess of the attenuated Sabin strain of poliovirus was protective against diseas

36 can enhance viral titers of both attenuated (Sabin strain) and wild-type polioviruses, a finding that

37 rable in efficacy to the currently available Sabin type 1 vaccine strain, but have the added advantag

38 ributable to interference of Sabin type 3 by Sabin type 2.

39 study, simulating 1 year of tOPV cessation, Sabin 2 transmission was higher in household contacts of

40 itch, 58% of environmental samples contained Sabin poliovirus; starting 6 weeks after the switch, Sab

41 1 possesses broader immunogenicity than does Sabin 2.

42 Committee dealing with these agents--Enders,Sabin, Dalldorf, Syverton--have passed on, but the work

43 .2% to 93.5%) and 93.2% (88.6% to 96.3%) for Sabin 1 and 3 poliovirus alone or in mixtures when teste

44 e-derived poliovirus (cVDPV) is 300 days for Sabin-like virus type 1, 210 days for Sabin-like virus t

45 ys for Sabin-like virus type 1, 210 days for Sabin-like virus type 2, and 390 days for Sabin-like vir

46 or Sabin-like virus type 2, and 390 days for Sabin-like virus type 3.

47 hat VP1 substitution rates are increased for Sabin-like isolates relative to the rate for the wild ty

48 We combine our observations for Sabin-like virus evolution with the molecular clock for

49 DPV, the recombination rates are similar for Sabin isolate-Sabin isolate and Sabin isolate-non-Sabin

50 ntibodies, and stool samples were tested for Sabin strain polioviruses.

51 g vaccine-derived polioviruses (cVDPV2) from Sabin oral poliovirus vaccines (OPVs) are the leading ca

52 y that directly detects PV2 RNA derived from Sabin-2 vaccine in wastewater and stool samples.

53 rived poliovirus (cVDPV2; >1% divergent from Sabin 2) occurred during July 2005-June 2010, a period w

54 virus (VDPV) with a 1.1% sequence drift from Sabin type 1 vaccine strain in the VP1 coding region 6 m

55 he assay is specific for PV2 originated from Sabin-2 vaccine and identifies 98.3% of available sequen

56 cine-associated paralytic poliomyelitis from Sabin oral poliovirus vaccines (OPVs) has stimulated dev

57 capsid coding region of nOPV2 with that from Sabin 1 or 3.

58 igenic divergence of the iVDPV variants from Sabin 1 followed two major independent evolutionary path

59 quences in neutralizing epitopes varied from Sabin 1 and Mahoney, with little variation among WPV1 is

60 and vaccine-derived polioviruses (VDPV) from Sabin-like strains.

61 In 8 patients who had Sabin-Feldman dye test titers >64 and for whom the infec

62 ssion analysis, fecal shedding of homologous Sabin strains was associated with increased seroresponse

63 Our results imply how Sabin OPV2 can be used alongside the genetically stable

64 Key determinants of attenuation in Sabin 1 had reverted in the iVDPV isolates, and represen

65 in humans, we studied molecular evolution in Sabin-like poliovirus isolates from Nigerian acute flacc

66 ted region, the primary site of reversion in Sabin OPV.

67 d mutagenesis of the miR-134 binding site in Sabin-1 IRES relieved miR-134-mediated repression indica

68 ve of recently acquired T. gondii infection (Sabin-Feldman dye test [DT] titers from 1:256 to 1:32,00

69 bination rates are similar for Sabin isolate-Sabin isolate and Sabin isolate-non-Sabin enterovirus re

70 hermore, the T cells also recognize and kill Sabin 1 vaccine-infected targets.

71 valent oral poliovirus vaccine (OPV) lacking Sabin 2.

72 be more genetically stable than the licensed Sabin monovalent OPV2, have been developed to respond to

73 gammaglobulinemic patient received monotypic Sabin 3 vaccine in 1962.

74 el OPV candidates compared with a monovalent Sabin OPV in children and infants.

75 ama: a control phase 4 study with monovalent Sabin OPV2 before global cessation of monovalent OPV2 us

76 adjuvant for currently used and proposed new Sabin IPVs.

77 fter the campaign, following 7 weeks with no Sabin strains detected.

78 isolate-Sabin isolate and Sabin isolate-non-Sabin enterovirus recombination after accounting for the

79 ants shows that while recombination with non-Sabin enteroviruses is associated with cVDPV, the recomb

80 wed miR-134 binding to Sabin-1 and 3 but not Sabin-2 IRES.

81 34) can regulate Sabin-1 replication but not Sabin-2 or Sabin-3 via direct interaction with the PV 5'

82 ine point mutation at nucleotide (nt) 472 of Sabin oral poliovirus vaccine (OPV) type 3 is found in c

83 tropism of poliovirus and the attenuation of Sabin vaccine strains.

84 ruses sharing a 367-nucleotide (nt) block of Sabin 1-derived sequence spanning the VP1 and 2A genes c

85 Comparison of Sabin-like virus recombinants with known Nigerian vaccin

86 OPV formulations with higher doses of Sabin type 3 could improve immunogenicity among infants

87 transcripts containing the IRES elements of Sabin type 1 poliovirus or encephalomyocarditis virus, c

88 The evolution of Sabin 3 throughout the entire period of virus excretion

89 amples containing up to a 100-fold excess of Sabin vaccine strain-related sequences of the same serot

90 ssion to observe prevalence and incidence of Sabin 2 virus.

91 as primarily attributable to interference of Sabin type 3 by Sabin type 2.

92 Six pairs of Sabin strain-specific recombinant primers were designed

93 ained the temperature-sensitive phenotype of Sabin 1.

94 e in some way to the attenuated phenotype of Sabin type I.

95 ated and temperature-sensitive phenotypes of Sabin 3.

96 Polioviruses of Sabin types 2 and 3 reverted more easily than those of t

97 the structural and nonstructural proteins of Sabin strains may equally contribute to the attenuation

98 in which the entire 5' noncoding regions of Sabin 1 and Sabin 2 were replaced exactly with that of o

99 Replication of Sabin strains used in oral poliovirus vaccine (OPV) in t

100 mechanism of miR-134-mediated repression of Sabin-1.

101 We aimed to assess the risk of Sabin 2 transmission after a polio vaccination campaign

102 The pI's of Sabin types 1, 2, and 3 viruses were 7.4, 7.2, and 6.3,

103 ive mOPV2, as assessed by faecal shedding of Sabin 2 by reverse transcriptase quantitative PCR (RT-qP

104 However, faecal shedding of Sabin 2 in household contacts was increased significantl

105 Faecal shedding of Sabin 2 in infants who did not receive the mOPV2 challen

106 gineered to improve the genetic stability of Sabin oral poliovirus vaccine (OPV) and reduce the emerg

107 r tolerability and immunogenicity to that of Sabin type 2 vaccines to mitigate the risk of cVDPV2.

108 l 1991) isolates completely matched those of Sabin 1.

109 of a miR-134 mimic repressed translation of Sabin-1 5'UTR driven luciferase validating the mechanism

110 ps indicated transient local transmission of Sabin-like virus type 3 and, possibly, Sabin-like virus

111 All isolates were antigenic variants of Sabin 1, having multiple amino acid substitutions within

112 ceived OPV were found to contain variants of Sabin vaccine viruses.

113 Since the global withdrawal of Sabin 2 oral poliovirus vaccine (OPV) from routine immun

114 o end game, which includes the withdrawal of Sabin strains, starting with type 2, and the introductio

115 adication endgame required the withdrawal of Sabin type 2 from the oral poliovirus vaccine and introd

116 New poliovirus vectors based on Sabin 1 and 2 vaccine strain viruses were constructed, a

117 ion-PCR (qRT-PCR) assay for detection of OPV Sabin strains 1, 2, and 3 directly in stool samples with

118 ulate Sabin-1 replication but not Sabin-2 or Sabin-3 via direct interaction with the PV 5'UTR.

119 mucosal immune responses induced by nOPV2 or Sabin mOPV2 and observed the strongest responses in infa

120 e-attenuated oral poliovirus vaccine (OPV or Sabin vaccine) replicates in gut-associated tissues, eli

121 risk of transmission of type 2 poliovirus or Sabin 2 virus on re-introduction or resurgence of type 2

122 immunogenicity comparable to their parental Sabin strains, but are more attenuated.

123 and 11 were highly active against poliovirus Sabin 1-3.

124 in-house chemical library against poliovirus Sabin strains led to the identification of compounds 5 a

125 on of Sabin-like virus type 3 and, possibly, Sabin-like virus type 1 during periods of low wild polio

126 lts from the toxoplasma serological profile (Sabin-Feldman dye test, conventional IgM and IgA ELISAs,

127 ween these two tests, a serological profile (Sabin-Feldman dye test, IgA and IgE antibody tests, diff

128 d considerable divergence from the prototype Sabin strain in all cases.

129 the type 1 live-attenuated poliovirus (PV) (Sabin) vaccine containing a human rhinovirus type 2 (HRV

130 the type 1 live-attenuated poliovirus (PV) (Sabin) vaccine containing a human rhinovirus type 2 (HRV

131 that microRNA-134-5p (miR-134) can regulate Sabin-1 replication but not Sabin-2 or Sabin-3 via direc

132 el, we present a simulation of mOPV2-related Sabin 2 transmission in rural Matlab, Bangladesh based o

133 Reversion of shed Sabin-2 virus corresponded with unadjusted paralysis rat

134 ss-protection following DENV infection since Sabin's challenge studies in the 1940s.

135 for sIPV was established, with new, specific Sabin D-antigen units assigned.

136 lower than those against the vaccine strain Sabin-1, two genetically distinct WPV1s isolated in 1965

137 liovirus; starting 6 weeks after the switch, Sabin polioviruses were rarely isolated, and if they wer

138 The Sabin vaccine strains used in prevention of poliomyeliti

139 the Coalition Against Typhoid, based at the Sabin Vaccine Institute, convened the 10th International

140 the Coalition against Typhoid, based at the Sabin Vaccine Institute, convened the 11th International

141 sequence (nt 3271 to 3637) derived from the Sabin 1 oral poliovirus vaccine strain spanning the 3'-t

142 o poliovirus populations, differing from the Sabin 1 vaccine strain by approximately 10%, differing f

143 The iVDPV isolates differed from the Sabin type 1 oral poliovirus vaccine (OPV) strain at 1.8

144 differences in nucleotide sequence from the Sabin type 1 strain.

145 uence for antigenic site 3a derived from the Sabin type 2 strain.

146 differences in nucleotide sequence from the Sabin type 3 vaccine.

147 own to be caused by viruses derived from the Sabin vaccine strains.

148 e IgM ELISA, 71 (46.4%) were negative in the Sabin-Feldman dye test.

149 Like the Sabin-Feldman dye test, the new test is based on complem

150 poliovirus strains derived from Mahoney, the Sabin 1 vaccine strain and the mouse-adapted LS-a virus.

151 % correlation with the reference method, the Sabin-Feldman dye test for the detection of Toxoplasma I

152 two major determinants of attenuation of the Sabin 2 oral poliovirus vaccine strain (A481 in the 5'-u

153 The RdRp of the Sabin I vaccine strain has Thr-362 changed to Ile.

154 h the attenuating IRES point mutation of the Sabin serotype 1 vaccine strain.

155 ucleotide 480-G was identical to that of the Sabin strain.

156 Neuron-specific propagation deficits of the Sabin strains are partially encrypted within a confined

157 own that the attenuated viral genomes of the Sabin strains direct levels of viral protein synthesis l

158 ces were not closely related to those of the Sabin strains or 53 diverse contemporary wild poliovirus

159 ontinued because of the inherent risk of the Sabin strains to revert to neurovirulence and reacquire

160 amino acids within the capsid region of the Sabin type 2 oral poliovirus vaccine strain with corresp

161 to-U mutation at base 472 in the IRES of the Sabin type 3 poliovirus vaccine strain, known to attenua

162 n directing the attenuation phenotype of the Sabin vaccine strain of poliovirus type 1.

163 All three serotypes of the Sabin vaccine strains and the P3/Leon strain of poliovir

164 tral nervous system (CNS) attenuation of the Sabin vaccine strains of poliovirus (PV) are located wit

165 er and interpret data about evolution of the Sabin viruses used in OPV in regions where cVDPV has occ

166 merges due to the genetic instability of the Sabin viruses used in the oral polio vaccine (OPV) in po

167 sks of reverting to neurovirulence) than the Sabin monovalent OPV2 (mOPV2), has been deployed to inte

168 to 97% nucleotide sequence identity) to the Sabin type 2 oral poliovirus vaccine (OPV) strain and un

169 Despite their effectiveness as vaccines, the Sabin strains retain a neuropathogenic potential in anim

170 tics are observed in cells infected with the Sabin 1 vaccine strain.

171 A translation defect associated with the Sabin type 3 IRES was observed in all organs examined.

172 Samples were tested with the Sabin-Feldman dye test and a range of agglutination assa

173 globulin G (IgG) and IgM IMx assays with the Sabin-Feldman dye test and an IgM enzyme-linked immunoso

174 test were similar to those obtained with the Sabin-Feldman dye test run in parallel.

175 new test which were not perceptible with the Sabin-Feldman dye test.

176 s for attenuating point mutations within the Sabin strains.

177 he 5' UTR and P1 genomic region in all three Sabin serotypes, as well as vaccine-related viruses with

178 n simply and quantitatively detect all three Sabin strains directly in stool samples to approximate s

179 veloped neutralizing antibodies to all three Sabin types and also exhibited higher rates of polioviru

180 Binding of miR-134 to Sabin-1 IRES caused degradation of the IRES transcript i

181 abin type 1, 97% to Sabin type 2, and 61% to Sabin type 3 vaccines.

182 Seroresponses were 86% to Sabin type 1, 97% to Sabin type 2, and 61% to Sabin type

183 roresponses were 86% to Sabin type 1, 97% to Sabin type 2, and 61% to Sabin type 3 vaccines.

184 ypochromicity data showed miR-134 binding to Sabin-1 and 3 but not Sabin-2 IRES.

185 oresponses to all Sabin types, especially to Sabin type 3.

186 Several manufacturers use Sabin OPV strains for IPV production (sIPV), rather than

187 Although stem-loop V Sabin mutations have been proposed to alter RNA secondar

188 ng of the VP1 region to distinguish vaccine (Sabin), vaccine-derived, and wild-type polioviruses and

189 The primary outcome was Sabin 2 incidence in the 10 weeks after the campaign in

190 tional recombination beyond the initial wild-Sabin recombination event.

191 e the phased cessation of OPV (starting with Sabin type 2) and emphasized the need for affordable IPV

192 Vaccination with Sabin, a live attenuated oral polio vaccine (OPV), resul